App-Quantinova.ai

An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderately to Severely Active RA

Kevin Winthrop - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Filgotinib

ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository

Irene Cecchi - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study

Amy Trang - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Cutaneous lupus erythematosus

N/A

Analysis of Emergency Department Visits by Patients with Giant Cell Arteritis: A National Population-based Study

Amy Trang - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

N/A

ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain

Naomi Patel - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Glucocorticoid

Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?

Sinead Maguire - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Are Virtual Cognitive Assessments Comparable to In-person Assessments in a Systemic Lupus Erythematosus Cohort?

Michelle Barraclough - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

ASAS Recommendations for Requesting and Reporting Imaging in Patients with Suspected Axial Spondyloarthritis

Denis Poddubnyy - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update

Sofia Ramiro - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Association of Urban vs. Rural Residence with New DMARD Initiation in US Veterans with Active Rheumatoid Arthritis

Luke Desilet - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Prednisone

Associations of Serum C3f with Selected Biomarkers and Radiographic and Clinical Features of Knee Osteoarthritis

Yulia Liem - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Knee osteoarthritis

N/A

Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets

Ronald Van Vollenhoven - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

MDX1333

Autoantibodies and Damage in Patients with Idiopathic Inflammatory Myopathies: A Longitudinal Multicenter Study from the EuroMyositis International Network

Fabricio Espinosa-Ortega - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic inflammatory myopathies

N/A

Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease

Sarah Tansley - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Interstitial lung disease

N/A

Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease

Anna Nagel - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study

Athimalaipet Ramanan - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

Baseline Characteristics of and Early Outcomes in the First 200 Patients with RA Treated with Filgotinib in a Prospective Observational Study

James Galloway - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Filgotinib

Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus

Muhammad Shipa - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Belimumab

Belimumab Disrupts Memory B-Cell Trafficking in Patients with Systemic Lupus Erythematosus

Onno Teng - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Belimumab

Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials

Jorge Sanchez-Guerrero - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Belimumab

Filters

45280 Abstracts